Advanced Functional Materials - Rapid Personalized Therapeutic Cancer Vaccines

We've published breakthrough research in Advanced Functional Materials that could transform how we prevent cancer from coming back after surgery. Our team developed a personalized cancer vaccine that can be produced in just 72 hours using the patient's own tumor cells—a dramatic improvement over current cell therapies that take 6-8 weeks.

Here's how it works: we take tumor cells removed during surgery and engineer them with an attenuated bacteria strain to increase the response they trigger when exposed to immune cells. These modified cells are then combined with L-arginine and delivered through dissolving micro-needle patches that patients can receive right at the surgical site.

The system works through three mechanisms: it amplifies presentation of the patient's specific tumor antigens, reprograms immune-suppressive macrophages into tumor-fighting cells, and generates nitric oxide that triggers inflammatory cell death in any remaining cancer cells. Specifically, the bacterial components activate the NF-κB signaling pathway, which drives macrophages to produce high levels of iNOS—an enzyme that converts the supplied L-arginine into toxic nitric oxide that kills tumor cells.

When we tested this approach in mouse models of incomplete melanoma resection, the results were remarkable. The vaccine reduced tumor regrowth by 92.7% without any other treatment, including complete remission in 20% of cases. Even more importantly, we show these vaccines have a strong abscopal effect meaning that the immune system learns to fight cancer cells anywhere in the body, not just at the micro-needle application site. 

What makes this especially promising is the speed and personalization. Unlike generic cancer vaccines, this approach uses each patient's actual tumor cells, ensuring coverage of their unique cancer signature. The rapid 72-hour production timeline means treatment can begin while the immune system is still primed from surgery.

We are excited about expanding this work out to other cancer types in the future. 

Free Preprint
Full Text at AFM